vs
安朗杰（ALLE）与NEOGENOMICS INC（NEO）财务数据对比。点击上方公司名可切换其他公司
安朗杰的季度营收约是NEOGENOMICS INC的5.4倍（$1.0B vs $190.2M）。NEOGENOMICS INC同比增速更快（10.6% vs 9.3%）。安朗杰自由现金流更多（$200.5M vs $-6.5M）。过去两年NEOGENOMICS INC的营收复合增速更高（10.3% vs 7.5%）
安朗杰是全球知名的安防产品及解决方案供应商，面向全球生产销售机械与电子类安防产品，包括闭门器、出入口控制设备、锁具、电子门禁系统、考勤与人员效能管理系统、门体系统及相关配件，服务商业、公共机构、住宅等多领域终端用户
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
ALLE vs NEO — 直观对比
营收规模更大
ALLE
是对方的5.4倍
$190.2M
营收增速更快
NEO
高出1.3%
9.3%
自由现金流更多
ALLE
多$207.0M
$-6.5M
两年增速更快
NEO
近两年复合增速
7.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $190.2M |
| 净利润 | $147.5M | — |
| 毛利率 | 44.5% | 43.8% |
| 营业利润率 | 20.3% | -7.1% |
| 净利率 | 14.3% | — |
| 营收同比 | 9.3% | 10.6% |
| 净利润同比 | 2.4% | — |
| 每股收益（稀释后） | $1.70 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALLENEO
| Q4 25 | $1.0B | $190.2M | ||
| Q3 25 | $1.1B | $187.8M | ||
| Q2 25 | $1.0B | $181.3M | ||
| Q1 25 | $941.9M | $168.0M | ||
| Q4 24 | $945.6M | $172.0M | ||
| Q3 24 | $967.1M | $167.8M | ||
| Q2 24 | $965.6M | $164.5M | ||
| Q1 24 | $893.9M | $156.2M |
净利润ALLENEO
| Q4 25 | $147.5M | — | ||
| Q3 25 | $188.4M | $-27.1M | ||
| Q2 25 | $159.7M | $-45.1M | ||
| Q1 25 | $148.2M | $-25.9M | ||
| Q4 24 | $144.1M | — | ||
| Q3 24 | $174.2M | $-17.7M | ||
| Q2 24 | $155.4M | $-18.6M | ||
| Q1 24 | $123.8M | $-27.1M |
毛利率ALLENEO
| Q4 25 | 44.5% | 43.8% | ||
| Q3 25 | 45.8% | 42.8% | ||
| Q2 25 | 45.6% | 42.6% | ||
| Q1 25 | 44.9% | 43.6% | ||
| Q4 24 | 44.1% | 44.9% | ||
| Q3 24 | 44.7% | 44.6% | ||
| Q2 24 | 44.4% | 44.1% | ||
| Q1 24 | 43.8% | 41.9% |
营业利润率ALLENEO
| Q4 25 | 20.3% | -7.1% | ||
| Q3 25 | 21.8% | -14.4% | ||
| Q2 25 | 21.5% | -26.3% | ||
| Q1 25 | 20.9% | -16.6% | ||
| Q4 24 | 19.5% | -10.7% | ||
| Q3 24 | 22.2% | -12.6% | ||
| Q2 24 | 21.6% | -13.3% | ||
| Q1 24 | 19.3% | -19.6% |
净利率ALLENEO
| Q4 25 | 14.3% | — | ||
| Q3 25 | 17.6% | -14.4% | ||
| Q2 25 | 15.6% | -24.9% | ||
| Q1 25 | 15.7% | -15.4% | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 18.0% | -10.5% | ||
| Q2 24 | 16.1% | -11.3% | ||
| Q1 24 | 13.8% | -17.3% |
每股收益（稀释后）ALLENEO
| Q4 25 | $1.70 | — | ||
| Q3 25 | $2.18 | — | ||
| Q2 25 | $1.85 | — | ||
| Q1 25 | $1.71 | — | ||
| Q4 24 | $1.65 | — | ||
| Q3 24 | $1.99 | — | ||
| Q2 24 | $1.77 | — | ||
| Q1 24 | $1.41 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $356.2M | $159.6M |
| 总债务越低越好 | $2.0B | $341.9M |
| 股东权益账面价值 | $2.1B | $836.6M |
| 总资产 | $5.2B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.96× | 0.41× |
8季度趋势，按日历期对齐
现金及短期投资ALLENEO
| Q4 25 | $356.2M | $159.6M | ||
| Q3 25 | $302.7M | $164.1M | ||
| Q2 25 | $656.8M | $154.7M | ||
| Q1 25 | $494.5M | $346.2M | ||
| Q4 24 | $503.8M | $367.0M | ||
| Q3 24 | $878.9M | $362.0M | ||
| Q2 24 | $747.5M | $355.1M | ||
| Q1 24 | $391.8M | $331.9M |
总债务ALLENEO
| Q4 25 | $2.0B | $341.9M | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | $541.1M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.0B | — |
股东权益ALLENEO
| Q4 25 | $2.1B | $836.6M | ||
| Q3 25 | $1.9B | $838.3M | ||
| Q2 25 | $1.8B | $854.0M | ||
| Q1 25 | $1.6B | $888.3M | ||
| Q4 24 | $1.5B | $902.3M | ||
| Q3 24 | $1.6B | $908.2M | ||
| Q2 24 | $1.4B | $915.9M | ||
| Q1 24 | $1.4B | $923.4M |
总资产ALLENEO
| Q4 25 | $5.2B | $1.4B | ||
| Q3 25 | $5.2B | $1.4B | ||
| Q2 25 | $4.9B | $1.4B | ||
| Q1 25 | $4.6B | $1.6B | ||
| Q4 24 | $4.5B | $1.6B | ||
| Q3 24 | $5.0B | $1.6B | ||
| Q2 24 | $4.8B | $1.6B | ||
| Q1 24 | $4.3B | $1.6B |
负债/权益比ALLENEO
| Q4 25 | 0.96× | 0.41× | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 1.33× | 0.60× | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 1.69× | — | ||
| Q1 24 | 1.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $240.1M | $1.3M |
| 自由现金流经营现金流 - 资本支出 | $200.5M | $-6.5M |
| 自由现金流率自由现金流/营收 | 19.4% | -3.4% |
| 资本支出强度资本支出/营收 | 3.8% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.63× | — |
| 过去12个月自由现金流最近4个季度 | $685.7M | $-21.8M |
8季度趋势，按日历期对齐
经营现金流ALLENEO
| Q4 25 | $240.1M | $1.3M | ||
| Q3 25 | $229.5M | $8.9M | ||
| Q2 25 | $209.7M | $20.3M | ||
| Q1 25 | $104.5M | $-25.3M | ||
| Q4 24 | $219.0M | $9.8M | ||
| Q3 24 | $231.9M | $9.2M | ||
| Q2 24 | $173.0M | $13.9M | ||
| Q1 24 | $51.1M | $-25.9M |
自由现金流ALLENEO
| Q4 25 | $200.5M | $-6.5M | ||
| Q3 25 | $209.8M | $570.0K | ||
| Q2 25 | $192.0M | $14.0M | ||
| Q1 25 | $83.4M | $-29.8M | ||
| Q4 24 | $194.9M | $-1.8M | ||
| Q3 24 | $212.0M | $-1.6M | ||
| Q2 24 | $152.1M | $814.0K | ||
| Q1 24 | $23.9M | $-31.5M |
自由现金流率ALLENEO
| Q4 25 | 19.4% | -3.4% | ||
| Q3 25 | 19.6% | 0.3% | ||
| Q2 25 | 18.8% | 7.7% | ||
| Q1 25 | 8.9% | -17.8% | ||
| Q4 24 | 20.6% | -1.0% | ||
| Q3 24 | 21.9% | -0.9% | ||
| Q2 24 | 15.8% | 0.5% | ||
| Q1 24 | 2.7% | -20.2% |
资本支出强度ALLENEO
| Q4 25 | 3.8% | 4.1% | ||
| Q3 25 | 1.8% | 4.4% | ||
| Q2 25 | 1.7% | 3.5% | ||
| Q1 25 | 2.2% | 2.7% | ||
| Q4 24 | 2.5% | 6.7% | ||
| Q3 24 | 2.1% | 6.4% | ||
| Q2 24 | 2.2% | 8.0% | ||
| Q1 24 | 3.0% | 3.6% |
现金转化率ALLENEO
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 1.52× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALLE
| Products | $750.2M | 73% |
| Allegion International | $237.7M | 23% |
| Services | $45.2M | 4% |
NEO
| Client Direct Billing | $133.4M | 70% |
| Commercial Insurance | $31.4M | 17% |
| Medicare And Other Governmental | $25.4M | 13% |
